Parameter
| Biomarker | sPD-L1 | Full name | Soluble programmed death-ligand 1 | Molecular Type | Protein (soluble immune checkpoint molecule) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Assessment of disease status |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Plasm (ELISA、Luminex) | ||
| Pathobiological Mechanisms | High expression of PD-L1 in the tumor microenvironment leads to its release into the plasma, reflecting an immunosuppressive state, but is not directly correlated with total PD-L1 expression in tissues. | ||||
| Clinical Availability Status | Research phase: Significantly elevated compared to the healthy control group, and correlated with clinical indicators. | ||||
| Notes and Dynamics | It does not reflect tissue PD-L1 expression and requires analysis in conjunction with biopsy samples; future studies should explore its association with ICB treatment response. | ||||